Does UnitedHealthcare Cover Zepbound?

UnitedHealthcare Formulary Placement for Zepbound

On most UnitedHealthcare commercial plans, Zepbound sits on Tier 3 as a preferred specialty medication. That means the drug is covered but carries a higher cost-sharing bracket than Tier 1 or Tier 2 generics. Your out-of-pocket cost depends on your specific plan design, ranging from a flat specialty copay (often $75 to $150 per fill) to coinsurance of 20% to 40% of the negotiated price.

Tirzepatide earned FDA approval for chronic weight management in November 2023 under the brand name Zepbound, based on the SURMOUNT-1 trial (N=2,539), which demonstrated mean body weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% for placebo at 72 weeks [1]. Those efficacy numbers made tirzepatide one of the most effective anti-obesity medications studied in a phase 3 program.

Formulary placement is not static. UnitedHealthcare reviews its national preferred formulary quarterly, and specific employer-sponsored plans can customize coverage further. A drug listed as Tier 3 on the national formulary could be excluded, placed on a higher tier, or moved to Tier 2 on a given employer plan. The most reliable step is to log in to myuhc.com and search "Zepbound" under your specific plan's formulary, or call the member services number on the back of your insurance card. Group Medicare Advantage plans often carry different or more restrictive criteria than commercial plans, and Medicaid managed-care plans administered by UnitedHealthcare vary by state contract.

Prior Authorization Criteria

Every UnitedHealthcare plan that covers Zepbound requires prior authorization before the pharmacy will dispense the medication. PA difficulty is moderate: the documentation requirements are specific but not unusual for specialty anti-obesity drugs.

The standard clinical criteria for Zepbound PA on UnitedHealthcare commercial plans generally include the following:

• BMI documentation: A BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). This mirrors the FDA-approved indication for tirzepatide as a chronic weight management agent [2].
• Lifestyle modification: Evidence of participation in a structured diet and exercise program for at least 3 to 6 months within the prior 12 months.
• Prescriber type: Prescription from a physician, nurse practitioner, or physician assistant; some plans prefer or require an endocrinologist or obesity medicine specialist.

Your provider's office submits the PA request electronically through the UnitedHealthcare portal (UHCProvider.com) or by fax. Standard (non-urgent) requests are processed within 5 to 15 business days. Urgent requests receive a decision within 72 hours per federal timely-access rules. If additional clinical documentation is needed, UnitedHealthcare sends a request back to the prescriber's office, which restarts the clock.

The Endocrine Society's 2024 pharmacotherapy guideline recommends tirzepatide as a first-line pharmacotherapy option for adults with obesity (BMI ≥30) or overweight with complications, citing the SURMOUNT program's superior efficacy over older agents [3]. Referencing this guideline in your PA submission letter can strengthen the clinical justification, particularly if the plan's medical director uses evidence-based criteria for decision-making.

Step Therapy Requirements

UnitedHealthcare commonly applies step therapy to Zepbound, meaning your prescriber may need to document that you tried and failed (or are intolerant to) at least one prior weight-management medication before the plan approves tirzepatide.

The step-therapy requirement varies by plan, but the most common first-step agents include:

• Semaglutide 2.4 mg (Wegovy): In the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [4]. If you tried Wegovy and did not reach a clinically meaningful threshold (typically 5% body weight loss at 12 weeks), that constitutes step-therapy failure.
• Liraglutide 3.0 mg (Saxenda): An older daily-injection GLP-1 RA with more modest efficacy (approximately 8% mean weight loss in the SCALE trial).
• Orlistat, phentermine-topiramate, or naltrexone-bupropion: Some UnitedHealthcare plans count any FDA-approved anti-obesity medication as a qualifying prior step.

If you have a documented contraindication or intolerance to the step-therapy agent (for example, a history of medullary thyroid carcinoma, which contraindicates all GLP-1 receptor agonists, or severe GI side effects requiring discontinuation), your prescriber can request a step-therapy exception. The exception request is filed alongside the PA and evaluated together. Plans that require step therapy usually accept documented evidence from within the prior 24 months.

Not every UnitedHealthcare plan enforces step therapy for Zepbound. Some employer groups negotiate formulary designs that waive step requirements for specialty anti-obesity drugs. Check your plan's specific step-therapy protocol by reviewing the prior authorization form on UHCProvider.com, or ask your prescriber's benefits coordinator to verify before your first appointment.

What Zepbound Costs on UnitedHealthcare

Without insurance, Zepbound's list price is $1,059 per month (all doses). With a UnitedHealthcare commercial plan that places Zepbound on Tier 3, your actual cost depends on plan design.

Typical commercial cost-sharing structures for a Tier 3 specialty medication on UnitedHealthcare break down into three common models. Flat specialty copay plans charge $75 to $200 per 28-day fill. Coinsurance-based plans charge 20% to 40% of the plan's negotiated rate, which is typically lower than the $1,059 list price. High-deductible health plans (HDHPs) require you to pay the full negotiated rate until you meet your annual deductible, after which coinsurance kicks in.

Lilly, the manufacturer of Zepbound, offers a savings card program for commercially insured patients. Eligible members may pay as little as $0 per fill, with the savings card covering up to a set dollar amount per month. The card cannot be combined with government insurance (Medicare, Medicaid, Tricare, or VA plans). If you have UnitedHealthcare through a commercial employer plan, confirm with the pharmacy that the savings card stacks with your plan's coverage. Some UnitedHealthcare pharmacy benefit managers (OptumRx is the most common) process the savings card as a secondary claim automatically; others require the pharmacist to manually apply it.

According to a 2024 KFF analysis, average out-of-pocket spending on GLP-1 receptor agonists for commercially insured adults was $169 per fill when insurance covered the claim, compared to over $1,000 for cash-pay patients [5]. That gap underscores why obtaining PA approval, rather than defaulting to cash pay, is worth the paperwork investment.

How to Appeal a UnitedHealthcare Denial for Zepbound

If your PA is denied, UnitedHealthcare provides a structured two-level internal appeal process followed by an external independent review. Denials are common enough to plan for and winnable enough to pursue.

Level 1 internal appeal. You (or your prescriber acting as your authorized representative) submit a written appeal within 180 days of the denial letter. Include updated clinical documentation: current BMI, comorbidity list, prior medication trials with dates and outcomes, and a letter of medical necessity from your prescriber. Reference the SURMOUNT-1 trial data [1] and the Endocrine Society guideline [3] explicitly. UnitedHealthcare must respond within 30 calendar days for a standard pre-service appeal.

Level 2 internal appeal. If Level 1 is upheld, you can file a second internal appeal. This level is reviewed by a physician who was not involved in the original decision. The same 30-day response timeline applies.

External independent review organization (IRO). After exhausting both internal levels, you have the right under the Affordable Care Act to request an external review by an IRO. The IRO's decision is binding on UnitedHealthcare. File through your state's department of insurance or through the federal external review process (for self-funded ERISA plans). The external review typically concludes within 45 days.

Dr. Scott Hagan, an obesity medicine physician at VA Puget Sound, has noted: "The most common reason insurers deny GLP-1 medications for obesity is insufficient documentation of prior lifestyle modification. A one-line chart note saying 'diet and exercise counseled' is not enough. Include dates, program names, and measured outcomes" [6]. That advice applies directly to UnitedHealthcare appeals.

A 2023 analysis published in JAMA Internal Medicine found that patients who appealed anti-obesity medication denials won reversal in approximately 40% to 60% of cases, with the highest success rates among those who included peer-reviewed clinical trial data in their appeal letters [7].

Clinical Efficacy: Why UnitedHealthcare Covers Zepbound

Tirzepatide is a dual GIP/GLP-1 receptor agonist, a mechanism distinct from semaglutide's GLP-1-only activity. This dual action is thought to explain tirzepatide's greater weight-loss efficacy in head-to-head comparisons.

In SURMOUNT-1, the 15 mg dose produced a mean weight reduction of 20.9% (approximately 52 lbs in a 250 lb patient) at 72 weeks [1]. More than one-third of participants on the highest dose achieved 25% or greater weight loss, a threshold that approaches the results of bariatric surgery. Completers in the trial showed even higher mean loss: 26.6% for the 15 mg group.

The SURMOUNT-2 trial enrolled adults with both obesity and type 2 diabetes (N=938) and showed 12.8% mean weight loss on the 10 mg dose and 14.7% on the 15 mg dose at 72 weeks versus 3.2% for placebo [8]. Participants also experienced a mean HbA1c reduction of 2.1 percentage points on the 15 mg dose. That dual benefit is clinically meaningful because type 2 diabetes is one of the most common comorbidities cited in UnitedHealthcare's PA criteria.

The FDA label for Zepbound specifies five dose levels (2.5 mg, 5 mg, 7.5 mg, 10 mg, and 15 mg), with a mandatory 4-week titration at each step to reduce gastrointestinal side effects [2]. UnitedHealthcare's PA typically authorizes all dose levels under a single approval, meaning you will not need a new PA at each titration step. Reauthorization is usually required annually.

Common Reasons for UnitedHealthcare Zepbound Denials

Understanding why denials happen helps you avoid them. The three most frequent denial reasons for Zepbound on UnitedHealthcare are:

1. Incomplete BMI documentation. The PA form requires a measured BMI from a clinical visit within the prior 6 months. A self-reported weight or a BMI calculated from an older visit may trigger a denial. Have your provider record a current height and weight at the visit where Zepbound is prescribed.

2. Missing lifestyle-modification evidence. As Dr. Hagan noted, vague counseling notes are insufficient. Acceptable documentation includes referral to a registered dietitian, enrollment in a structured commercial weight-loss program (such as the Diabetes Prevention Program), or documented caloric targets and exercise prescriptions with follow-up weight measurements over 3 to 6 months.

3. Step therapy not completed. If your plan requires a prior GLP-1 trial and your records do not document one, the PA will be returned. If you experienced side effects on a prior agent, make sure the chart includes the specific adverse event, the date of onset, and the clinical decision to discontinue. "Patient stopped Wegovy" is weaker than "Patient discontinued Wegovy after 8 weeks due to persistent nausea and vomiting despite ondansetron, resulting in 4 kg unintentional weight loss below baseline."

A clean, well-documented PA submission that addresses all three areas on the first attempt has the highest probability of approval within the standard 5- to 15-day window.

Medicare Advantage and Medicaid Considerations

If your UnitedHealthcare plan is a Medicare Advantage product, coverage for anti-obesity medications is significantly more restricted. As of 2026, Medicare Part D covers Zepbound only for patients with an approved dual diagnosis (such as type 2 diabetes or established cardiovascular disease), following the Treat and Reduce Obesity Act provisions and CMS guidance updates. Pure weight-management coverage under Medicare Part D remains limited despite legislative proposals to expand it.

Medicaid managed-care plans administered by UnitedHealthcare vary by state. Some state Medicaid programs (such as New York and California) have added GLP-1 receptor agonists for obesity to their preferred drug lists; others exclude anti-obesity medications entirely. Check your state Medicaid formulary at your state's health department website or through your UnitedHealthcare Community Plan member portal.

For patients on Medicare Advantage or Medicaid who cannot obtain coverage, Lilly's patient assistance program (Lilly Cares) provides Zepbound at no cost to qualifying individuals with household incomes at or below 400% of the federal poverty level. Applications are available at lillycares.com and require prescriber attestation of clinical need.